-
公开(公告)号:EP4333829A1
公开(公告)日:2024-03-13
申请号:EP22728125.0
申请日:2022-05-05
申请人: Centre National de la Recherche Scientifique (CNRS) , Centre Hospitalier Universitaire de Montpellier , Institut National de la Santé et de la Recherche Médicale (INSERM) , Institut Curie , UNIVERSITE DE MONTPELLIER
IPC分类号: A61K31/198 , A61K31/35 , A61K31/454 , A61K38/07 , A61P35/02
-
2.
公开(公告)号:EP4055193A1
公开(公告)日:2022-09-14
申请号:EP20800210.5
申请日:2020-11-06
申请人: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , Centre Hospitalier Universitaire de Montpellier , Institut National de la Santé et de la Recherche Médicale (INSERM) , UNIVERSITE DE MONTPELLIER , Institut Curie
IPC分类号: C12Q1/6886
-
3.
公开(公告)号:EP4055194A1
公开(公告)日:2022-09-14
申请号:EP20800211.3
申请日:2020-11-06
申请人: Centre National de la Recherche Scientifique (CNRS) , Centre Hospitalier Universitaire de Montpellier , Institut National de la Santé et de la Recherche Médicale (INSERM) , UNIVERSITE DE MONTPELLIER , Institut Curie
IPC分类号: C12Q1/6886
-
公开(公告)号:EP2898091B1
公开(公告)日:2019-10-02
申请号:EP13766076.7
申请日:2013-09-23
申请人: Institut National de la Santé et de la Recherche Médicale (INSERM) , Université de Montpellier I , Centre Hospitalier Universitaire de Montpellier
发明人: MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号: C12Q1/6886 , A61K31/7068
-
公开(公告)号:EP3458860A1
公开(公告)日:2019-03-27
申请号:EP17726243.3
申请日:2017-05-22
申请人: Horiba ABX SAS / Horiba Ltd , Centre Hospitalier Universitaire de Montpellier , Institut National de la Santé et de la Recherche Médicale (INSERM) , Université de Montpellier
发明人: REQUIRAND, Guilhem , KLEIN, Bernard , REME, Thierry , MOREAUX, Jérôme , RAIMBAULT, Sébastien , NERIN, Philippe , PLANTEFEVE, Rosalie , ALATERRE, Elina , GARCIA, Jean-Michel
IPC分类号: G01N33/574 , G01N15/14 , G01N33/50
-
公开(公告)号:EP2898091A1
公开(公告)日:2015-07-29
申请号:EP13766076.7
申请日:2013-09-23
申请人: Institut National de la Santé et de la Recherche Médicale (INSERM) , Université de Montpellier I , Centre Hospitalier Universitaire de Montpellier
发明人: MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号: C12Q1/68 , A61K31/7068
CPC分类号: C12Q1/6886 , A61K31/706 , A61K31/7068 , C12Q2600/106 , C12Q2600/158 , G06F19/3456 , G16B25/00
摘要: The present invention relates to a method of testing whether a patient suffering of multiple myeloma will respond or not to a DNA methyltransferase inhibitor (DNMTi) comprising: i. determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii. comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii. calculating the DMS score trough the following formula (I) wherein &bgr;1 represent the regression &bgr; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score DMS determined at step iii) with a predetermined reference value DMSR and concluding that the patient will respond to the DNMTi when the DMS score is higher than the predetermined reference value DMSR or concluding that the patient will not respond to the DNMTi when the DMS score is lower than the predetermined reference value DMSR. DMS = ∑ i = 1 n &bgr; i × Ci ( I )
摘要翻译: 本发明涉及一种测试患有多发性骨髓瘤的患者是否会对DNA甲基转移酶抑制剂(DNMTi)起反应的方法,包括:i。 测定从所述患者ii获得的生物样品中选自表A的几个基因G I-G n的表达水平(ELi)。 将步骤i)确定的表达水平(ELi)与预定参考水平(ELRi)iii进行比较。 通过以下公式(I)计算DMS得分,其中如果基因G i(ELi)的表达高于预定参考水平(ELRi),则其表示基因G i和Ci = 1的回归β系数参考值, 或如果基因(ELi)的表达低于或等于预定参考水平(ELRi),则Ci = -1,将步骤iii)确定的评分DMS与预定参考值DMSR进行比较,并推断患者将响应 当DMS分数高于预定参考值DMS R时,向DNMTi发送该分数,或者当DMS分数低于预定参考值DMS R时,推断患者不会响应DNMTi。
-
公开(公告)号:EP3255433A1
公开(公告)日:2017-12-13
申请号:EP16305682.3
申请日:2016-06-09
申请人: Centre Hospitalier Universitaire de Montpellier , Centre National de la Recherche Scientifique CNRS , UNIVERSITE DE MONTPELLIER
IPC分类号: G01N33/574
CPC分类号: G01N33/57426 , G01N33/57407 , G01N2333/99 , G01N2800/52
摘要: The present invention relates to the use of an expression level value of BLM in a sample obtained from an individual affected with multiple myeloma for predicting responsiveness of the said individual to a treatment of multiple myeloma.
摘要翻译: 本发明涉及从受多发性骨髓瘤影响的个体获得的样品中BLM表达水平值用于预测所述个体对多发性骨髓瘤治疗的反应性的用途。
-
公开(公告)号:EP3252165A1
公开(公告)日:2017-12-06
申请号:EP16305651.8
申请日:2016-06-03
申请人: Centre National de la Recherche Scientifique (C.N.R.S.) , UNIVERSITE DE MONTPELLIER , Centre Hospitalier Universitaire de Montpellier
发明人: ALATERRE, Elina , MOREAUX, Jérôme
IPC分类号: C12Q1/68
CPC分类号: C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N33/57407 , G01N2333/70578 , G01N2333/70596
摘要: The present invention relates to the use of an expression level value of each of the four markers selected in a group consisting of CD24, CD27, CD36 and CD302 in a sample obtained from an individual affected with a multiple myeloma for predicting an outcome of a multiple myeloma in the said individual.
摘要翻译: 本发明涉及从受多发性骨髓瘤影响的个体获得的样品中选自由CD24,CD27,CD36和CD302组成的组中的四种标志物中的每一种的表达水平值用于预测多重结果 所述个体中的骨髓瘤。
-
9.
公开(公告)号:EP3995830A1
公开(公告)日:2022-05-11
申请号:EP20306351.6
申请日:2020-11-06
申请人: Centre national de la recherche scientifique , UNIVERSITE DE MONTPELLIER , Centre Hospitalier Universitaire de Montpellier
IPC分类号: G01N33/574 , C12Q1/6886
摘要: The present invention relates to a method for the in vitro prognosis of the likelihood of an individual having multiple myeloma to be sensitive to a therapeutic treatment, comprising the following steps
a) Measuring, in a biological sample of the individual, the level of expression of at least five genes, to obtain a individual value
b) Comparing the individual value obtained in a) with a reference value,
c) Classifying the individual as sensitive to the treatment if the individual value is modified when compared with the reference value.-
公开(公告)号:EP2904108B1
公开(公告)日:2019-05-22
申请号:EP13773791.2
申请日:2013-10-08
申请人: INSERM - Institut National de la Santé et de la Recherche Médicale , UNIVERSITE DE MONTPELLIER , Centre Hospitalier Universitaire de Montpellier
发明人: MOREAUX, Jérôme , KLEIN, Bernard
IPC分类号: C12Q1/6886
-
-
-
-
-
-
-
-
-